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ABSTRACT
Objective: The present study aims to examine the relationships
between and among cancer treatment‑related decisional
conflict, quality of life, and comorbidity in older adults with
cancer. Methods: A convenience sample of 200 older adults
was recruited from outpatient medical oncology and radiation
oncology practices in the northeastern United States.
A cross‑sectional, descriptive, correlational study design was
used employing a survey method. Survey instruments included
the Decisional Conflict scale (DCS) (with five subscales, including
informed, values clarity, support, uncertainty, and effective
decision); Self‑administered comorbidity questionnaire (SCQ);
European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (including five function scales,
three symptom scales, a global health/quality of life scale, and six
single items); and an investigator‑developed demographic form.
Results: The mean total DCS score was 22.1 (±12.5). The uncertainty

subscale had the highest mean of the subscales (29.2 ± 18.2).
The mean score for global health status/quality of life was
44.2 (±20.7). The mean score of the SCQ was low (9.6 ± 4.1).
Significant positive relationships were identified between
decisional conflict and quality of life (P = 0.009) and quality of life
and comorbidity (P = 0.001). Multiple linear regression analysis
found statistically significant relationships for total decisional
conflict score and the five decisional conflict scale subscales.
Conclusions: Results may suggest a relationship between
decisional conflict and quality of life, as well as the quality of
life and comorbidity. In addition, there are several physical,
emotional, and spiritual factors that may positively or negatively
impact decisional conflict.

Introduction

and nearly 70% of cancer deaths occur in people 65 years
of age and older in the United States.[1] As the population

It is widely accepted that the single greatest risk factor
for cancer is age. Greater than 50% of new cancer cases
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ages, this proportion will markedly increase. The incidence
of comorbid illness also increases with age. On an average,
people 65 years of age and over, with cancer, suffer from
three additional diseases.[2,3] Comorbidity is associated with
reduced life expectancy and increased risk for treatment
complications, while also having the potential to negatively
affect the natural history of cancer.[4‑7]
Regardless of age, cancer treatment‑related decisions can
be exceedingly complex. There is variability in patients’ desire
to participate in decision making, which may be influenced
by their age and disease progression.[8‑10] In addition, there is
a variety of psychological, physical, functional, and social
factors that influence decision‑making.[11‑14] Quality of life
is a concept that is central to the care of cancer patients.
Quality of life is generally described as a subjective and
multidimensional concept that encompasses many of the
components that influence decision making.[15] The concept
of quality of life refers to a broad range of content, including
physical functioning or well‑being, psychological well‑being,
social role functioning or well‑being, disease‑ and
treatment‑related symptoms, and spiritual well‑being.[15]
According to O’Connor,[16] patients’ health status (including
physical, emotional, cognitive, and social) is an essential
component in determining their decisional needs.
Measurement of comorbid illness and quality of life are
just two ways in which to gain some insight into a patient’s
health status and ultimately, decisional needs.
With an increasing number of cancer treatments
available, patients are presented with increasingly difficult
decisions. These decisions can lead to decisional conflict,
which can be described as “a state of uncertainty about
which course of action to take when choices among
competing actions involve risk, loss, regret, or challenge to
personal life values.”[17] Physiologic and psychologic factors
can be the basis for patients’ decision‑making. For older
adults, decisions regarding treatment may be considered in
the context of their physical function. Sometimes, patients
will choose to forego cancer treatment explicitly within the
context of their age and comorbidities.[18] Decision‑making
is preceded by careful thought, which is influenced by
a broad perspective of older adults’ values and their
perceptions of their whole life situation.[19,20]
As the proportion of older adults in the world increases,
so too will the prevalence of cancer. Cancer will be just one
of the chronic illnesses that older adults will endure. Older
adults are at risk for physical, psychological, and functional
decline as a result of these chronic illnesses, which may
be exacerbated by cancer and cancer treatment. Cancer
treatment‑related decisions are multifactorial and complex
for health‑care providers, patients, and families. Although
physicians utilize clinical tools in making decisions
422

regarding cancer treatment, little is known about how
older adults make their own decisions regarding treatment
and whether they experience decisional conflict regarding
those decisions.
The purpose of this study was to examine the relationships
between and among treatment‑related decisional conflict,
comorbid illness, and quality of life in older adults with
cancer. The following research questions guided this
inquiry:
1. What is the relationship between and among
treatment‑related decisional conflict, quality of life,
and comorbidity in older adults with cancer
2. To what degree does the variability in the quality of life
and level of comorbidity predict decisional conflict?

Methods
Sample and design
This study utilized a cross‑sectional, descriptive,
correlational study design using a survey method. A sample
of 200 older adults with cancer was recruited from two
medical oncology practices and one radiation oncology
practice in the northeastern United States.
With the permission of the practices, flyers advertising
the study were developed by the investigator and placed in
waiting rooms and examination rooms. Interested patients
were directed to contact any nurse in the practice. If patients
who met the inclusion criteria were identified by nurses, a
survey packet was offered to them. Once completed, the
survey packet was returned to the nurse and the patient
received a $10 gift card.
The criteria for inclusion in this study were as follows:
being 65 years of age or older, English‑speaking, having
the ability to read English at an eighth‑grade level, having
a current cancer diagnosis, and receiving cancer treatment.
A power analysis was conducted to determine the
appropriate sample size to conduct correlational statistics
and regression analysis. Using the effect size as a guideline,
a sample size range of 193 (d = 0.40) to 346 (d = 0.30) was
calculated. Thus, a sample size of 193 was needed to achieve
the power of 0.80 using a two‑tailed test of significance
at 0.05.

Data collection instruments
Par ticipants were asked to complete four
instruments including Decisional Conflict Scale (DCS),
Self‑Administered Comorbidity Questionnaire (SCQ),
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ‑C30),
and an investigator‑developed Demographic Information
Form (DIF).
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The DCS was developed to elicit “healthcare consumers’
uncertainty in making a health‑related decision, the
factors contributing to the uncertainty, and health‑care
consumers’ perceived effective decision‑making.”[21] There
are four versions of the DCS; however, the traditional
DCS was used in this study because it has been used
in >30 studies and sufficient psychometric data exist.[22] The
traditional DCS is a 16‑item instrument that consists of five
subscales: informed (items 1–3); values clarity (items 4–6);
support (items 7–9); uncertainty (items 10–12); and effective
decision (items 13–16). Items in each subscale are scored
on a 5‑point Likert scale (0 = strongly agree, 1 = agree,
2 = neither agree nor disagree, 3 = disagree, and 5 = strongly
disagree). DCS scores range from 0 (no decisional conflict)
to 100 (extremely high‑decisional conflict). According to
O’Connor,[22] investigators using the DCS should “set the
stage” for participants by asking them to focus on their
opinions regarding a treatment decision specific to the
area of inquiry. To this end, the investigator developed an
opening paragraph to the DCS that focused respondents
to cancer treatment‑related decisions, an open‑ended
question to determine the decision that was made, and a
multiple choice question to determine when the decision
was made. The paragraph and questions were pilot‑tested
with a sample (n = 10) that met the inclusion criteria for the
current study. Minor logistical revisions were made based
on the pilot study. In this study, reliability analyses indicated
acceptable reliability with Cronbach’s α > 0.70 for the DCS
total score and each of the subscales.
The SCQ allows participants to note the severity of
each comorbid disease and their perception of its impact
on their function. It is a 13‑item instrument with the option
of adding three additional conditions in an open‑ended
format. Thirteen medical conditions are listed for which
participants are asked to indicate if they have the condition,
if they receive treatment for the condition, and if the
condition limits their activities. For each item, participants
record a dichotomous yes or no response. A maximum of
three points can be scored for each medical condition: one
point for the presence of the medical condition, one point
if treatment is received for the medical condition, and
one point if the medical condition causes a limitation in
functioning. The total number of points depends on whether
or not the optional open‑ended items are completed by the
participant (scale range 0–48). The SCQ has been shown to
have good reliability and validity in previous studies of older
adults;[23] however, in this study, the SCQ was not found to
have an acceptable level of reliability (Cronbach’s α = 0.36).
The EORTC QLQ‑C30 (Version 3) is a 30‑item instrument
that consists of multi‑item scales and single‑item measures
including five function scales (physical, role, cognitive,

emotional, and social); three symptom scales (fatigue, pain, and
nausea/vomiting); a global health status/quality of life scale;
and six single items (dyspnea, appetite, sleep, constipation,
diarrhea, and financial). The two global health status/quality
of life items are scored on a 7‑point Likert scale (1 = very
poor to 7 = excellent); the remaining 28 items are scored on
a 4‑point Likert scale (1 = not at all, 2 = a little, 3 = quite a
bit, and 4 = very much). All of the scales and single‑item
measures range in score from 0 to 100. A high score for global
health status/quality of life represents a high quality of life,
a high score for a functional scale indicates a high/healthy
level of functioning, and high score for a symptom scale/item
represents a high level of symptoms/problems.[24] The EORTC
QLQ‑C30 has been shown to have good reliability and validity
in numerous international oncology studies. In this study, the
EORTC QLQ‑C30 was found to have an acceptable level of
reliability with a Cronbach’s α of 0.88.
The DIF included 17 items to describe the population
under study. In addition to marital status, race, religion,
and education, participants were asked to specify the type
of cancer, types of cancer treatments received, and types
of decision support received.

Statistical analysis
Data were analyzed using IBM SPSS Statistics
Version 21 (IBM Corp., Armonk, NY, USA). Initially,
a series of descriptive statistics were conducted on the
demographic data and on the dependent variable, decisional
conflict, and independent variables, quality of life, and
comorbidity. Next, a series of correlations were conducted
to determine the relationship between the variables.
Histograms as well as additional descriptive analyses
conducted indicated that these measures were not normally
distributed; therefore, the assumptions of parametric testing
were not met. Thus, Spearman’s rho (rs), the nonparametric
equivalent of Pearson’s r, was used for the correlational
analyses. Scatterplots were used to test for the assumptions
of multiple regression. Since the scatterplots revealed
linearity, multivariate normality, homoscedasticity, and no
multicollinearity, multiple linear regression analyses were
conducted to determine whether the predictors of quality of
life and comorbidity significantly impact decisional conflict.

Ethical approval
The investigator received approval to conduct the
study from the Institutional Review Board of Duquesne
University. Participation in the study was voluntary, and
all participants had the right to refuse.

Results
The mean age (± standard deviation) of the participants
was 73.1 (±6.98), more than half were female, approximately
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half were married, and the majority were married. The most
common cancer diagnosis was lung cancer (23.1%), and
more than half (51.5%) indicated that cancer had spread.
Slightly over 41% of participants indicated they were
accompanied by spouses/significant others to appointments
with their cancer doctors. The highest grade of school
completed was found to be a mean of 13.1 years (±2.1),
with a minimum of 8 years and a maximum of 18 years of
schooling. The majority (71.5%) were retired. In terms of
decision support, almost all reported that their cancer doctor
helped them make decisions about their cancer treatment,
followed by family, and their cancer nurse. Table 1 shows
summary of the demographic characteristics of the sample.
When completing the DCS, the majority of
participants (59%) identified their complex decision as
related to chemotherapy, and 48% of the participants
indicated that they had made their decision within the last
3 months. Approximately 19% of participants had decided
over 1 year ago. Table 2 presents the other characteristics of
the complex decision reflected on in completing the DCS.
A summary of the descriptive statistics for the DCS,
EORTC QLQ‑C30, and SCQ is presented in Table 3.
Overall, the mean DCS total score (± standard deviation)
was low (22.1 ± 12.5) with subscale four (uncertainty)
having the highest mean (± standard deviation) of the
subscales (29.2 ± 18.2). The mean (± standard deviation)
score for the two global health status/quality of life
questions was 44.2 (±20.7). Of the function scales, cognitive
function had the highest mean score, while role function had
the lowest. Fatigue had the highest mean of the symptom
scales. With regard to the six single items, dyspnea had the
highest mean. The mean score of the SCQ was low, with the
most reported comorbid illness being high blood pressure.
The results of correlation analysis showed a significant
relationship between decisional conflict and quality
of life (P < 0.01) and between the quality of life and
comorbidity (P < 0.01). The correlation conducted between
decisional conflict and comorbidity failed to achieve
significance. Table 4 shows correlation coefficients for each
of the study variables.
Multiple linear regression analysis was conducted to
determine whether there were any predictors that significantly
impact the DCS total score and the five DCS subscales. All
components of the EORTC QLQ‑C30 were analyzed as
predictors, including five function scales, three symptom
scales, global health status/quality of life scale, and six single
items. Regression analysis also included total SCQ score and
elements of the DIF. All six of the regression models were
found to achieve statistical significance (P < 0.001). Tables 5‑10
summarize the results of the multiple regression analysis
conducted on DCS total and each of the DCS subscales.
424

Table 1: Demographic characteristics of study
participants (n=200*)
Characteristics
Age, years, Mean±SD, range

Data
73.1±7.0, 65‑92

Gender, n (%)
Female

102 (51.0)

Male

98 (49.0)

Marital status, n (%)
Married

101 (50.5)

Widowed

55 (27.5)

Divorced

32 (16.0)

Single, never married

12 (6.0)

Race, n (%)
White

175 (87.5)

African American

11 (5.5)

Hispanic

9 (4.5)

Native American/Eskimo

1 (0.5)

Asian

1 (0.5)

Missing

3 (1.5)

Religion, n (%)
Catholic

105 (52.5)

Protestant

48 (24.0)

Other Christian

26 (13.0)

Jewish

11 (5.5)

No affiliation

6 (3.0)

Jehovah Witness

1 (0.5)

Missing

3 (1.5)

Employment status, n (%)
Retired

143 (71.5)

Disabled

32 (16.0)

Employed part‑time

18 (9.0)

Employed full‑time

3 (1.5)

Missing

4 (2.0)

Cancer type, n (%)
Lung

46 (23.0)

Leukemia/myelodysplastic syndrome/lymphoma

32 (16.0)

Breast

24 (12.0)

Colorectal

23 (11.5)

Pancreas/gall bladder

13 (6.5)

Ovarian/uterine

12 (6.0)

Multiple myeloma

12 (6.0)

Head/neck

11 (5.5)

Prostate

9 (4.5)

Liver

6 (3.0)

Melanoma

4 (2.0)

Bladder

4 (2.0)

Kidney

2 (1.0)

Sarcoma

1 (0.5)

Missing

1 (0.5)

Has the cancer spread?, n (%)
No

103 (51.5)

Yes

97 (48.5)

Who primarily goes to cancer appointments with you?, n (%)
Spouse/significant other

81 (40.5)

Child

51 (25.5)

Alone

38 (19.0)

Other family

19 (9.5)

Contd...

Asia‑Pacific Journal of Oncology Nursing • Volume 5 • Issue 4 • October-December 2018

[Downloaded free from http://www.apjon.org on Tuesday, December 4, 2018, IP: 147.140.233.16]

Kates: Decisional Conflict, Quality of Life, and Comorbidity
Table 1: Contd...
Characteristics

Data

Friend

4 (2.0)

Paid caregiver

3 (1.5)

Missing

4 (2.0)

Resources/support/decision aids (list all that apply), n (%)
Cancer doctor

198 (99.0)

Family

160 (80.0)

Cancer nurse

74 (37.0)

Websites

32 (16.0)

Priest/minister/spiritual support

15 (7.5)

Support group

11 (5.5)

Books

8 (4.0)

Other, n (%)
Family doctor

1 (0.5)

Friends

5 (2.5)

Hypnotist

1 (0.5)

Nurse navigator

1 (0.5)

Social worker

1 (0.5)

Therapist

2 (1.0)

*n=200 reflects the total number of participants who initiated the survey. Not all items
were answered by all participants. SD: Standard deviation

Table 2: Characteristics of complex decisions (n=200*)
Response

n (%)

Type of decision
Chemotherapy

118 (59.0)

Radiation therapy

51 (25.5)

Surgery

18 (9.0)

Clinical trial

4 (2.0)

Second opinion

4 (2.0)

Cancer doctor/facility

3 (1.5)

Stem cell transplant

1 (0.5)

Missing

1 (0.5)

Length of time since decision was made
<3 months

94 (47.0)

3‑6 months

29 (14.5)

6‑9 months

18 (9.0)

9‑12 months

17 (8.5)

Over 1 year

38 (19.0)

Missing

4 (2.0)

*n=200 reflects the total number of participants who initiated the survey. Not all items
were answered by all participants

Discussion
Descriptive analysis revealed there was no decisional
conflict in this sample. A DCS score <25 indicates no
decision‑making difficulty.[22] The mean DCS total score
of 22.1 in this study demonstrated that, overall, the
participants in this study did not have difficulty with
decision making. Participants demonstrated a higher level
of decisional conflict in DCS subscale four which evaluates
how informed one is “about options, risks, and benefits,
and feeling clear about values and value tradeoffs in the
decision.”[21] A higher score in this subscale indicates that

participants felt less informed about options, risks, and
benefits and were unsure of personal values in making
cancer treatment‑related decisions.[21] It is unclear why
there were low levels of decisional conflict in this study. In
one study,[25] it was found that DCS scores may decrease
considerably up to 6 months posttreatment. Since almost
63% of this sample made the treatment‑related decision
within the last 6 months, the actual level of decisional
conflict may have been higher at the time of the decision. In
addition, the majority of this sample had lung cancer, and
regardless of cancer type, slightly more than half reported
that their cancer had spread. It is unknown whether cancer
type or stage may have an impact on decisional conflict,
thus further study is needed.
When compared with data from other studies of older
adults with cancer, the global health status/quality of life
of this sample was generally poorer. In a large study of
cancer patients to establish reference values for the EORTC
QLQ‑C30, the mean global health status/quality was found
to be 61.8 (ages 60–69) and 60.6 (ages 70 and older).[26]
Although different instruments were used to measure the
quality of life, the overall quality of life of this sample is
poorer than the quality of life of older adults with cancer or
advanced illness in other studies.[27,28] When compared with
the EORTC QLQ‑C30 reference values for patients 70 years
and older,[26] the participants in this study had a poorer
physical function, poorer role function, better emotional
function, similar cognitive function, and poorer social
function. With the exception of insomnia, the participants
in this study had higher mean scores on all symptom scales
and single items than the EORTC QLQ‑C30 reference
values. The mean insomnia scores were similar. The fact
that participants in this study, overall, had poorer role
function and worse symptomatology may account for the
poorer global health status/QOL.
The reported level of comorbidity by participants in this
study was higher than in other studies of older adults that
utilized the SCQ.[29,30] The most reported comorbid illnesses
were similar to the most reported illnesses in other studies
of older adults, including high blood pressure, back pain,
and lung disease.[23,30]
Family members were a source of support for the
participants in this study. About 77% of the sample
indicated that they were accompanied to appointments with
their cancer doctors by a spouse/significant other, child, or
other family members. The availability of a caregiver or a
family member influences treatment decisions.[31] Family
support was also essential in making decisions about
cancer treatment. In this sample, participants reported
multiple sources of support in making decisions about
cancer treatment. The most frequent included cancer
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Table 3: Descriptive statistics of study variables (n=200*)
Measure

n

Mean±SD

Range

DCS total

198

22.1 (12.5)

0‑70.3

DCS S1

200

21.7 (15.7)

0‑100

DCS S2

199

19.9 (13.7)

0‑100

DCS S3

200

19.1 (12.0)

0‑50

DCS S4

200

29.2 (18.2)

0‑100

DCS S5

199

21.0 (13.5)

0‑50

Global health status/QOL

200

44.2 (20.7)

0‑100

Physical function

200

64.1 (23.9)

0‑100

Role function

200

59.8 (28.6)

0‑100

Emotional function

200

79.0 (20.0)

8.3‑100

Cognitive function

200

80.1 (18.8)

16.7‑100

Social function

200

68.3 (25.3)

0‑100

Fatigue

200

41.4 (21.6)

0‑100

Nausea/vomiting

200

11.3 (17.7)

0‑83.3

Pain

200

30.6 (25.2)

0‑100

Dyspnea

200

28.3 (26.7)

0‑100

Insomnia

200

26.5 (27.2)

0‑100

Appetite loss

200

25.5 (26.5)

0‑100

Constipation

200

23.2 (29.6)

0‑100

Diarrhea

200

12.3 (21.5)

0‑100

Financial problems

198

22.7 (28.2)

0‑100

SCQ

200

9.6 (4.1)

3‑23

EORTC QLQ‑C30

*n=200 reflects the total number of participants who initiated the survey. Not all items
were answered by all participants. DCS: Decisional conflict scale, which consists of
a global score and five subscales: S1: Informed, S2: Values clarity, S3: Support, S4:
Uncertainty and S5: Effective decision, EORTC QLQ‑C30: European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire, SCQ: Self‑administered
comorbidity questionnaire, SD: Standard deviation

Table 4: Correlation coefficients of study variables
Variables

rs

P

Decisional conflict and quality of life

0.185

0.009

Quality of life and comorbidity

0.240

0.001

Decisional conflict and comorbidity

0.129

0.070

rs: Spearman’s rho

doctor, family, and cancer nurse. This is consistent with
other studies that demonstrated the importance of family
preference, family burden, and physician’s opinion in
making cancer‑related treatment decisions.[14,32]
One of the aims of this study was to examine the
relationship between and among decisional conflict, quality
of life, and comorbidity. Correlational analysis indicated
that decisional conflict was significantly correlated with
quality life. The weak, though positive and significant, the
correlation between decisional conflict and quality of life
indicates that greater treatment‑related decisional conflict
may be associated with greater quality of life. A study[33]
found that older adults with cancer chose their treatment
decisions depending on the burden of the treatment,
possible outcomes, and likelihood of adverse functional
and cognitive outcomes. However, to date, there have been
no published reports of the relationship between decisional
426

conflict and quality of life. Additional studies are needed
to validate the findings in this study.
The correlational analysis also indicated that quality
of life was significantly correlated with comorbidity. The
weak to moderate, though positive, correlation indicates
that greater quality of life may be associated with greater
comorbidity. This result must be interpreted cautiously
since the SCQ was not found to have an acceptable level
of reliability and thus, a Type I error may have occurred.
Finally, decisional conflict and comorbidity were not
found to be significantly correlated. However, due to the
low level of reliability of the SCQ, this result must also
be interpreted cautiously because a Type II error may
have occurred.
The other aim of this study was to determine the degree
to which quality of life and comorbidity predict decisional
conflict. The results of the regression analysis of this data
indicate that higher/healthier emotional function may be
predictive of lower decisional conflict. Previous studies
have documented a relationship between decisional conflict
and emotional status, with mixed results. In a study of
hospital patients,[34] the investigators found that a decrease
in decisional conflict leads to less fretting and nervousness.
Another study[35] found a similar relationship to the present
study with a negative predictive relationship between
anxiety and DCS.
Interestingly, of those physical symptoms that achieved
significance, a negative relationship was found. The
symptom of diarrhea (EORTC QLQ‑C30) was significant
in five of the six regression models, with the exception of
the informed subscale. Other symptoms that were found to
be significant included insomnia (values clarity subscale),
fatigue (support subscale), and nausea/vomiting (effective
decision subscale). This is a curious finding, as it would
seem that worse physical symptoms, especially if they
were treatment‑related, may increase decisional conflict.
Although an explanation for this finding is unclear, it may
be that participants felt that the symptoms are expected with
cancer treatment and thus, did not increase conflict in the
decision‑making process. Alternatively, if the symptoms are
cancer‑related, participants may have felt that the treatment
was helping them
Financial problems, reported as a component of the
EORTC QLQ‑C30, were found to be predictive of higher
DCS total, informed subscale, and uncertainty subscale.
Lack of insurance and having a poor financial status are
important contextual factors that can influence treatment
choice.[36] In this study, >87% identified as “retired” or
“disabled.” Although financial information and insurance
status were not collected in this study, it is reasonable
to suspect that this majority would have some financial
challenges or limitations being on a fixed income.
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Table 5 Regression model explaining scores reflecting
decisional conflict scale total
β

Variable

B

SE

Constant

38.654

11.081

Global health status/QOL

0.079

0.053

0.133

Physical function

0.072

0.055

Role function

−0.081

Emotional function

−0.201

Cognitive function

Table 7: Regression model explaining scores reflecting
decisional conflict scale subscale 2 (values clarity subscale)
SE

(Constant)

47.975

12.303

Global health status/QOL

0.010

0.058

0.016

0.177

0.859

0.190

Physical function

0.145

0.061

0.255

2.370

0.019*

−1.274

0.204

Role function

−0.132

0.071

−0.276

−1.866

0.064

−3.519

0.001**

Emotional function

−0.201

0.063

−0.293

−3.166

0.002**

−0.073

0.068

−0.102

−1.072

0.285

0.008

0.057

0.014

0.136

0.892

P

3.488

0.001

1.513

0.132

0.141

1.314

0.064

−0.186

0.057

−0.325

Variable

β

B

t

t

P

3.899

0.000

−0.028

0.061

−0.043

−0.454

0.650

Cognitive function

Social function

0.040

0.052

0.083

0.783

0.435

Social function

Fatigue

−1.24

0.079

−0.217

−1.564

0.120

Fatigue

−0.169

0.088

−0.269

−1.923

0.056

Nausea/vomiting

−0.068

0.056

−0.098

−1.209

0.228

Nausea/vomiting

−0.109

0.062

−0.142

−1.739

0.084

Pain

0.075

0.041

0.153

1.844

0.067

Pain

0.087

0.045

0.161

1.919

0.057

Dyspnea

0.026

0.037

0.056

0.696

0.488

Dyspnea

0.077

0.041

0.151

1.860

0.064

Insomnia

−0.055

0.034

−0.121

−1.608

0.110

Insomnia

−0.114

0.039

−0.230

−2.952

0.004**

Appetite loss

0.019

0.040

0.041

0.474

0.636

Appetite loss

0.028

0.044

0.055

0.630

0.529

Constipation

−0.011

0.031

−0.026

−0.344

0.731

Constipation

−0.012

0.035

−0.026

−0.334

0.738

Diarrhea

−0.131

0.041

−0.226

−3.173

0.002**

Diarrhea

−0.107

0.046

−0.167

−2.342

0.020*

0.076

0.033

0.173

2.269

0.024*

Financial problems

−0.045

0.227

−0.015

−0.199

0.842

SCQ

Financial problems
SCQ

*P<0.05; **P<0.01. F (16, 179)=3.299, P<0.001; adjusted R2=0.159. DCS: Decisional
conflict scale, QOL: Quality of life, SCQ: Self‑administered comorbidity questionnaire,
SE: Standard error

Table 6: Regression model explaining scores reflecting
decisional conflict scale subscale 1 (informed subscale)
Variable

B

SE

Constant

41.789

13.589

β

Cancer nurse helpful

0.065

0.037

0.135

1.764

0.079

−0.412

0.252

−0.125

−1.631

0.105

3.278

2.055

0.117

1.595

0.112

*P<0.05; **P<0.01. F (17, 179)=3.006, P<0.001; Adjusted R2=0.148. DCS: Decisional
conflict scale, QOL: Quality of life, SCQ: Self‑administered comorbidity questionnaire,
SE: Standard error

Table 8: Regression model explaining scores reflecting
decisional conflict scale subscale 3 (support subscale)

t

P

3.075

0.002

Variable

B

SE

1529.501

472.413

β

t

P

3.238

0.001

Global health status/QOL

0.066

0.065

0.088

1.029

0.305

Constant

Physical function

0.084

0.069

0.129

1.220

0.224

Global health status/QOL

0.089

0.051

0.154

1.730

0.085

Role function

−0.077

0.078

−0.141

−0.988

0.324

Physical function

0.059

0.054

0.121

1.101

0.273

Emotional function

−0.191

0.070

−0.245

−2.722

0.007**

Role function

−0.114

0.061

−0.272

−1.851

0.066

Cognitive function

−0.170

0.075

−0.207

−2.256

0.025*

Emotional function

−0.140

0.055

−0.236

−2.538

0.012*

0.118

0.063

0.191

1.854

0.065

Cognitive function

0.021

0.059

0.033

0.350

0.727

−0.148

0.097

−0.206

−1.522

0.130

Social function

0.023

0.050

0.049

0.455

0.650

−0.167

0.077

−0.304

−2.177

0.031

−0.025

0.055

−0.038

−0.456

0.649

Social function
Fatigue

−0.062

0.069

−0.071

−0.895

0.372

Fatigue

Pain

0.041

0.050

0.066

0.814

0.417

Nausea/vomiting

Dyspnea

0.090

0.046

0.155

1.964

0.051*

Pain

0.052

0.039

0.111

1.323

0.187

Insomnia

−0.075

0.042

−0.133

−1.788

0.075

Dyspnea

0.033

0.036

0.074

0.902

0.368

Appetite loss

−0.050

0.049

−0.086

−1.026

0.306

Insomnia

−0.004

0.033

−0.010

−0.136

0.892

Constipation

0.036

0.039

0.069

0.923

0.357

Appetite loss

0.041

0.039

0.093

1.059

0.291

−0.090

0.050

−0.125

−1.796

0.074

Constipation

−0.038

0.030

−0.095

−1.261

0.209

Diarrhea

−0.133

0.039

−0.244

−3.392

0.001**
0.076

Nausea/vomiting

Diarrhea
Financial problems

0.130

0.041

0.235

3.165

SCQ

0.185

0.282

0.049

0.655

0.002**
0.513

Financial problems

0.057

0.032

0.137

1.782

Spiritual support person

−9.486

4.065

−0.162

−2.334

0.021*

SCQ

−0.138

0.221

−0.048

−0.625

0.533

Other resources

−7.233

4.508

−0.107

−1.605

0.110

Year diagnosed

−0.744

0.235

−0.223

−3.171

0.002**

*P≤0.05; **P<0.01. F (18, 179)=3.678, P<0.001, Adjusted R2=0.197. DCS: Decisional
conflict scale. QOL: Quality of life, SCQ: Self‑administered comorbidity questionnaire,
SE: Standard error

In addition to decisional conflict and quality of life,
components of the DIF were included in the regression
analysis. The presence of spiritual support has been
shown to impact treatment‑related decisions.[37] In this
study, the use of a spiritual support person for decision
making significantly decreased scores in the informed and
effective decision subscales. There are no published studies

*P<0.05; **P<0.01. F (17, 176)=3.107, P<0.001; Adjusted R2=0.157. DCS: Decisional
conflict scale, QOL: Quality of life, SCQ: Self‑administered comorbidity questionnaire,
SE: Standard error

examining the relationship between spiritual support and
decisional conflict; however, the results of this study are
suggestive of spiritual support lowering some components
of decisional conflict.

Limitations
There are several limitations that impact the
generalizability of the findings of this study. It is important
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Table 9: Regression model explaining scores reflecting
decisional conflict scale subscale 4 (uncertainty subscale)
β

Variable

B

SE

Constant

48.454

16.382

Global health status/QOL

0.123

0.077

0.140

Physical function

0.014

0.081

Role function

−0.042

Emotional function
Cognitive function

t

P

2.958

0.004

1.591

0.113

0.019

0.175

0.862

0.094

−0.066

−0.448

0.655

−0.233

0.084

−0.257

−2.766

0.006**

−0.090

0.090

−0.094

−0.992

0.323

0.021

0.076

0.029

0.271

0.786

Fatigue

−0.172

0.117

−0.206

−1.461

0.146

Nausea/vomiting

−0.080

0.083

−0.079

−0.958

0.339

0.115

0.060

0.160

1.918

0.057

Dyspnea

−0.010

0.056

−0.015

−0.175

0.861

Insomnia

−0.061

0.050

−0.092

−1.207

0.229

Appetite loss

0.029

0.059

0.043

0.502

0.617

Constipation

0.001

0.046

0.001

0.014

0.989

−0.146

0.061

−0.174

−2.395

0.018*

Financial problems

0.105

0.049

0.164

2.140

0.034*

SCQ

0.001

0.337

0.000

0.002

0.998

Chemotherapy

7.224

3.892

0.135

1.856

0.065

Social function

Pain

Diarrhea

*P<0.05, **P<0.01. F (17, 180)=2.957; P<0.001; adjusted R2=0.144. DCS: Decisional
conflict scale, QOL: Quality of life, SCQ: Self‑administered comorbidity questionnaire,
SE: Standard error

Table 10: Regression model explaining scores reflecting
decisional conflict scale subscale 5 (effective decision subscale)
Variable

B

SE

Constant

28.155

12.055

Global health status/QOL

0.117

0.057

Physical function

β
0.180

t

P

2.336

0.021

2.039

0.043*

0.050

0.060

0.090

0.838

0.403

Role function

−0.024

0.069

−0.051

−0.344

0.731

Emotional function

−0.239

0.062

−0.356

−3.847

0.000**

Cognitive function

0.121

0.067

0.171

1.818

0.071

Social function

−0.022

0.056

−0.042

−0.398

0.691

Fatigue

−0.101

0.086

−0.163

−1.169

0.244

Nausea/vomiting

−0.132

0.061

−0.176

−2.159

0.032*

Pain

0.073

0.044

0.137

1.648

0.101

Dyspnea

−0.009

0.041

−0.019

−0.233

0.816

Insomnia

−0.030

0.037

−0.060

−0.792

0.429

Appetite loss

0.061

0.043

0.121

1.405

0.162

Constipation

−0.006

0.035

−0.014

−0.177

0.859

Diarrhea

−0.133

0.045

−0.214

−2.979

0.003**

Financial problems

0.036

0.036

0.076

0.999

0.319

SCQ

0.156

0.250

0.048

0.623

0.534

−10.956

3.563

−0.217

−3.075

0.002**

Spiritual support person

*P<0.05; **P<0.01. F (17, 179)=3.096, P<0.001, adjusted R2=0.154. DCS: Decisional
conflict scale, QOL: Quality of life, SCQ: Self‑administered comorbidity questionnaire,
SE: Standard error

to recognize that these data are reflective of a group of
predominantly white cancer patients from a suburban area
and are not representative of the nation. Therefore, the
results of this study may not be generalizable to individuals
with different demographic characteristics. All of the data
utilized in this study was self‑reported, which could impact
the accuracy of the data. Although study participation
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was voluntary and anonymous, it is possible that not
all participants were comfortable exploring some of the
psychosocial or emotional components of the surveys.
Since most of the participants reported that they do not
go to their appointments alone, the surveys may have been
completed in the presence of someone else. This may have
affected their responses. Furthermore, about comorbidity, it
is possible that the SCQ was not the best instrument to use
in this population given the low Cronbach’s alpha.

Future research
Research that focuses on older adults with cancer is
limited in the literature. This was the first study to examine
the variables of decisional conflict, quality of life, and
comorbidity in older adults. Future research should focus on
the additional investigation of these variables, particularly
with a diverse sample, and to further validate these study
results. Since decisional conflict can diminish over time,
it would be helpful to repeat this study with patients who
are currently in the process of making a treatment‑related
decision and possibly, prospectively follow them over a
period. In light of the results of the regression analyses,
further research is indicated about emotional function,
spiritual support, and symptom management in the setting
of decision making in older adults with cancer.

Conclusion
This study examined the relationships between
decisional conflict, quality of life, and comorbidity in older
adults with cancer. Participants in this study were found to
experience decisional conflict in the uncertainty subscale,
have a poor quality of life, and suffer from cancer‑ and
treatment‑related symptoms. A relationship may exist
between decisional conflict and quality of life, as well as
the quality of life and comorbidity. With patient‑centered
care at its core, nursing is poised to empower patients to
communicate their needs, values, and preferences related
to treatment‑related decisions.
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